297 related articles for article (PubMed ID: 25825497)
21. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
Brown MA; Sims RJ; Gottlieb PD; Tucker PW
Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
[TBL] [Abstract][Full Text] [Related]
22. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
23. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
[TBL] [Abstract][Full Text] [Related]
24. An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates.
Ahmed H; Duan S; Arrowsmith CH; Barsyte-Lovejoy D; Schapira M
J Proteome Res; 2016 Jun; 15(6):2052-9. PubMed ID: 27163177
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis.
Kim K; Ryu TY; Jung E; Han TS; Lee J; Kim SK; Roh YN; Lee MS; Jung CR; Lim JH; Hamamoto R; Lee HW; Hur K; Son MY; Kim DS; Cho HS
Exp Mol Med; 2023 May; 55(5):952-964. PubMed ID: 37121971
[TBL] [Abstract][Full Text] [Related]
26. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
[TBL] [Abstract][Full Text] [Related]
27. The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.
Fan JD; Lei PJ; Zheng JY; Wang X; Li S; Liu H; He YL; Wang ZN; Wei G; Zhang X; Li LY; Wu M
PLoS One; 2015; 10(1):e0116782. PubMed ID: 25562686
[TBL] [Abstract][Full Text] [Related]
28. Identification of a peptide inhibitor for the histone methyltransferase WHSC1.
Morrison MJ; Boriack-Sjodin PA; Swinger KK; Wigle TJ; Sadalge D; Kuntz KW; Scott MP; Janzen WP; Chesworth R; Duncan KW; Harvey DM; Lampe JW; Mitchell LH; Copeland RA
PLoS One; 2018; 13(5):e0197082. PubMed ID: 29742153
[TBL] [Abstract][Full Text] [Related]
29. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.
Barsyte-Lovejoy D; Li F; Oudhoff MJ; Tatlock JH; Dong A; Zeng H; Wu H; Freeman SA; Schapira M; Senisterra GA; Kuznetsova E; Marcellus R; Allali-Hassani A; Kennedy S; Lambert JP; Couzens AL; Aman A; Gingras AC; Al-Awar R; Fish PV; Gerstenberger BS; Roberts L; Benn CL; Grimley RL; Braam MJ; Rossi FM; Sudol M; Brown PJ; Bunnage ME; Owen DR; Zaph C; Vedadi M; Arrowsmith CH
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12853-8. PubMed ID: 25136132
[TBL] [Abstract][Full Text] [Related]
30. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.
Wu J; Cheung T; Grande C; Ferguson AD; Zhu X; Theriault K; Code E; Birr C; Keen N; Chen H
Biochemistry; 2011 Jul; 50(29):6488-97. PubMed ID: 21678921
[TBL] [Abstract][Full Text] [Related]
31. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Reynoird N; Mazur PK; Stellfeld T; Flores NM; Lofgren SM; Carlson SM; Brambilla E; Hainaut P; Kaznowska EB; Arrowsmith CH; Khatri P; Stresemann C; Gozani O; Sage J
Genes Dev; 2016 Apr; 30(7):772-85. PubMed ID: 26988419
[TBL] [Abstract][Full Text] [Related]
32. Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.
Su H; Meng C; Xu J; Su Z; Xiao C; Yang D
Cell Death Dis; 2022 Oct; 13(10):890. PubMed ID: 36270984
[TBL] [Abstract][Full Text] [Related]
33. Purification of Histone Lysine Methyltransferase SMYD2 and Co-Crystallization with a Target Peptide from Estrogen Receptor α.
Jiang Y; Holcomb J; Spellmon N; Yang Z
Methods Mol Biol; 2016; 1366():207-217. PubMed ID: 26585137
[TBL] [Abstract][Full Text] [Related]
34. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
[TBL] [Abstract][Full Text] [Related]
36. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
[TBL] [Abstract][Full Text] [Related]
37. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
38. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
39. Molecular Cloning and Purification of the Protein Lysine Methyltransferase SMYD2 and its Co-crystallization with a Target Peptide from Estrogen Receptor Alpha.
Zhang Y; Yang Z
Methods Mol Biol; 2022; 2418():345-362. PubMed ID: 35119674
[TBL] [Abstract][Full Text] [Related]
40. The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3-SRF axis.
Zhong X; Wei X; Xu Y; Zhu X; Huo B; Guo X; Feng G; Zhang Z; Feng X; Fang Z; Luo Y; Yi X; Jiang DS
Acta Pharm Sin B; 2024 Feb; 14(2):712-728. PubMed ID: 38322347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]